OBJECTIVE: To establish phenotype-genotype correlations in early-onset Parkinson disease (EOPD), we performed neurologic, neuropsychological, and psychiatric evaluations in a series of patients with and without parkin mutations. BACKGROUND: Parkin (PARK2) gene mutations are the major cause of autosomal recessive parkinsonism. The usual clinical features are early-onset typical PD with a slow clinical course, an excellent response to low doses of levodopa, frequent treatment-induced dyskinesias, and the absence of dementia. METHODS: A total of 44 patients with EOPD (21 with and 23 without parkin mutations) and 9 unaffected single heterozygous carriers of parkin mutations underwent extensive clinical, neuropsychological, and psychiatric examinations. RESULTS: The neurologic, neuropsychological, and psychiatric features were similar in all patients, except for significantly lower daily doses of dopaminergic treatment and greater delay in the development of levodopa-related fluctuations (p < 0.05) in parkin mutation carriers compared to noncarriers. There was no major difference between the two groups in terms of general cognitive efficiency. Psychiatric manifestations (depression) were more frequent in patients than in healthy single heterozygous parkin carriers but did not differ between the two groups of patients. CONCLUSION: Carriers of parkin mutations are clinically indistinguishable from other patients with young-onset Parkinson disease (PD) on an individual basis. Severe generalized loss of dopaminergic neurons in the substantia nigra pars compacta in these patients is associated with an excellent response to low doses of dopa-equivalent and delayed fluctuations, but cognitive impairment and special behavioral or psychiatric symptoms were not more severe than in other patients with early-onset PD.
OBJECTIVE: To establish phenotype-genotype correlations in early-onset Parkinson disease (EOPD), we performed neurologic, neuropsychological, and psychiatric evaluations in a series of patients with and without parkin mutations. BACKGROUND: Parkin (PARK2) gene mutations are the major cause of autosomal recessive parkinsonism. The usual clinical features are early-onset typical PD with a slow clinical course, an excellent response to low doses of levodopa, frequent treatment-induced dyskinesias, and the absence of dementia. METHODS: A total of 44 patients with EOPD (21 with and 23 without parkin mutations) and 9 unaffected single heterozygous carriers of parkin mutations underwent extensive clinical, neuropsychological, and psychiatric examinations. RESULTS: The neurologic, neuropsychological, and psychiatric features were similar in all patients, except for significantly lower daily doses of dopaminergic treatment and greater delay in the development of levodopa-related fluctuations (p < 0.05) in parkin mutation carriers compared to noncarriers. There was no major difference between the two groups in terms of general cognitive efficiency. Psychiatric manifestations (depression) were more frequent in patients than in healthy single heterozygous parkin carriers but did not differ between the two groups of patients. CONCLUSION: Carriers of parkin mutations are clinically indistinguishable from other patients with young-onset Parkinson disease (PD) on an individual basis. Severe generalized loss of dopaminergic neurons in the substantia nigra pars compacta in these patients is associated with an excellent response to low doses of dopa-equivalent and delayed fluctuations, but cognitive impairment and special behavioral or psychiatric symptoms were not more severe than in other patients with early-onset PD.
Authors: R Hilker; C Klein; M Ghaemi; B Kis; T Strotmann; L J Ozelius; O Lenz; P Vieregge; K Herholz; W D Heiss; P P Pramstaller Journal: Ann Neurol Date: 2001-03 Impact factor: 10.422
Authors: C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice Journal: N Engl J Med Date: 2000-05-25 Impact factor: 91.245
Authors: A T Portman; N Giladi; K L Leenders; P Maguire; L Veenma-van der Duin; J Swart; J Pruim; E S Simon; S Hassin-Baer; A D Korczyn Journal: Neurology Date: 2001-06-26 Impact factor: 9.910
Authors: Andrew West; Magali Periquet; Sarah Lincoln; Christoph B Lücking; David Nicholl; Vincenzo Bonifati; Nina Rawal; Thomas Gasser; Ebba Lohmann; Jean-François Deleuze; Demetrius Maraganore; Allan Levey; Nick Wood; Alexandra Dürr; John Hardy; Alexis Brice; Matt Farrer Journal: Am J Med Genet Date: 2002-07-08
Authors: Naheed L Khan; David J Brooks; Nicola Pavese; Mary G Sweeney; Nicholas W Wood; Andrew J Lees; Paola Piccini Journal: Brain Date: 2002-10 Impact factor: 13.501
Authors: Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder Journal: Mov Disord Date: 2014-11-12 Impact factor: 10.338
Authors: Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder Journal: J Int Neuropsychol Soc Date: 2010-11-24 Impact factor: 2.892
Authors: Roy N Alcalay; Helen Mejia-Santana; Ming X Tang; Brian Rakitin; Llency Rosado; Barbara Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Lorraine N Clark; Karen S Marder; Elise Caccappolo Journal: J Clin Exp Neuropsychol Date: 2010-02-24 Impact factor: 2.475
Authors: Mario R Cornejo-Olivas; Luis Torres; Ignacio F Mata; Pilar Mazzetti; Diana Rivas; Carlos Cosentino; Miguel Inca-Martinez; Juan M Cuba; Cyrus P Zabetian; James B Leverenz Journal: Parkinsonism Relat Disord Date: 2015-01-15 Impact factor: 4.891
Authors: A Srivastava; M-X Tang; H Mejia-Santana; L Rosado; E D Louis; E Caccappolo; C Comella; A Colcher; A Siderowf; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; H Andrews; C Waters; S Fahn; L Cote; S Frucht; B Ford; R N Alcalay; B Ross; M Orbe Reilly; M Rezak; K Novak; J H Friedman; R D Pfeiffer; L Marsh; B Hiner; D Merle; R Ottman; L N Clark; K Marder Journal: Parkinsonism Relat Disord Date: 2011-12 Impact factor: 4.891
Authors: Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia L Comella; Martha A Nance; Susan B Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin E Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Bradley Hiner; Haydeh Payami; Eric Molho; Stewart A Factor; John G Nutt; Carmen Serrano; Maritza Arroyo; Ruth Ottman; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Karen S Marder Journal: JAMA Neurol Date: 2014-01 Impact factor: 18.302